{"nctId":"NCT02282813","briefTitle":"Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002","startDateStruct":{"date":"2013-04"},"conditions":["Chronic Kidney Disease","Hyperparathyroidism, Secondary","Vitamin D Deficiency"],"count":298,"armGroups":[{"label":"CTAP101 Capsules alone","type":"EXPERIMENTAL","interventionNames":["Drug: CTAP101 Capsules"]},{"label":"CTAP101 Capsules +calcitriol","type":"EXPERIMENTAL","interventionNames":["Drug: CTAP101 Capsules","Drug: Calcitriol"]},{"label":"CTAP101 Capsules +doxercalciferol","type":"EXPERIMENTAL","interventionNames":["Drug: CTAP101 Capsules","Drug: Doxercalciferol"]},{"label":"CTAP101 Capsules +paricalcitol","type":"EXPERIMENTAL","interventionNames":["Drug: CTAP101 Capsules","Drug: Paricalcitol"]}],"interventions":[{"name":"CTAP101 Capsules","otherNames":["Calcifediol"]},{"name":"Calcitriol","otherNames":["calcifediol"]},{"name":"Doxercalciferol","otherNames":["calcifediol"]},{"name":"Paricalcitol","otherNames":["calcifediol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completed either of the phase 3 double-blind, placebo-controlled studies, CTAP101-CL-3001 or CTAP101-CL-3002\n* Taking no more than 1000 mg/day of elemental Ca and willing/able to remain on this dose for the duration of the study\n* Taking no more than 1600 IU/dose vitamin D (ergocalciferol or cholecalciferol) therapy and willing/able to remain on a stable dose of vitamin D during the study\n* Willing and able to comply with study instructions and to commit to all clinic visits for the duration of the study\n* Female subjects of childbearing potential must be neither pregnant nor lactating and must have a negative urine pregnancy test\n* All female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective contraception (eg, implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence, vasectomy or vasectomized partner) for the duration of the study\n* Have the ability to read and understand subject Informed Consent Form (ICF). Subjects or their legal representatives must sign the ICF.\n\nExclusion Criteria:\n\n* Use of pharmacological dose of ergocalciferol and cholecalciferol (monthly equivalent of 50,000 IU or 1250 µg, eg, Drisdol®) or bisphosphonate therapy\n* Use of other bone metabolism therapy (with the exception of stable doses of bisphosphonates and denosumab \\[Xgeva® and Prolia®\\]) that may interfere with study endpoints\n* Concomitant serious illness or medical condition, such as malignancy, human immunodeficiency virus, significant gastrointestinal or hepatic disease or cardiovascular event or hepatitis that in the opinion of the investigator may worsen and/or interfere with participation in the study\n* Neurological/psychiatric disorder, including psychotic disorder or dementia, or any condition reason which, in the opinion of the investigator makes adherence to a treatment or follow-up schedule unlikely\n* Known or suspected hypersensitivity to any of the constituents of either investigational product (CTAP101) or adjunctive vitamin D hormone therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)","description":"Number of subjects in the intent to treat population with a mean reduction in plasma intact parathyroid hormone (iPTH) of \\>/= 30% from pretreatment baseline values at end of treatment (EOT), classified as responders","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in the Per Protocol Population With Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)","description":"Number of subjects in the per protocol population with a mean reduction in plasma intact parathyroid hormone (iPTH) of \\>/= 30% from pretreatment baseline values at end of treatment (EOT), classified as responders","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in the Intent to Treat Population With Normal Serum 25-hydroxyvitamin D at End of Treatment (EOT)","description":"Number of Participants in the Intent to Treat Population with serum 25-hydroxyvitamin D \\>/= 30 ng/mL at End of Treatment (EOT)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"124","spread":null},{"groupId":"OG002","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in the Per Protocol Population With NormalSerum 25-hydroxyvitamin D at End of Treatment (EOT)","description":"Number of Participants in the per protocol population with serum 25-hydroxyvitamin D \\>/= 30 ng/mL at End of Treatment (EOT)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"120","spread":null},{"groupId":"OG002","value":"37","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":103},"commonTop":["Anaemia","Nausea","Diarrhoea","Constipation","Urinary tract obstruction"]}}}